These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 33936080

  • 1. Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.
    Chen YL, Liu LX, Huang Q, Li XY, Hong XP, Liu DZ.
    Front Immunol; 2021; 12():654376. PubMed ID: 33936080
    [Abstract] [Full Text] [Related]

  • 2. Refractory alopecia in lupus treated with tofacitinib - a case-based review.
    Sarkar R, Mv P, Hinduja N, Sethy M, Kar H, Ahmed S.
    Clin Rheumatol; 2023 Aug; 42(8):2237-2241. PubMed ID: 37188961
    [Abstract] [Full Text] [Related]

  • 3. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW, Kehl A, Worswick S, Goh C.
    J Drugs Dermatol; 2018 Jul 01; 17(7):800-803. PubMed ID: 30005104
    [Abstract] [Full Text] [Related]

  • 4. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG, Liu LY, King BA.
    J Am Acad Dermatol; 2017 Jan 01; 76(1):29-32. PubMed ID: 27816292
    [Abstract] [Full Text] [Related]

  • 5. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N, Nour TM, Hussain NH.
    Dermatology; 2019 Jan 01; 235(2):130-136. PubMed ID: 30566941
    [Abstract] [Full Text] [Related]

  • 6. Non-scarring patchy alopecia in patients with systemic lupus erythematosus differs from that of alopecia areata.
    Ye Y, Zhao Y, Gong Y, Zhang X, Caulloo S, Zhang B, Cai Z, Yang J, McElwee KJ, Zhang X.
    Lupus; 2013 Dec 01; 22(14):1439-45. PubMed ID: 24132518
    [Abstract] [Full Text] [Related]

  • 7. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS, Huh CH, Kwon O, Yoon HS, Cho S, Park HS.
    J Dermatolog Treat; 2018 Dec 01; 29(8):819-822. PubMed ID: 29658800
    [Abstract] [Full Text] [Related]

  • 8. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A, Nguyen N, Cerise JE, Ulerio G, de Jong A, Clynes R, Christiano AM, Mackay-Wiggan J.
    Exp Dermatol; 2016 Aug 01; 25(8):642-3. PubMed ID: 27119625
    [No Abstract] [Full Text] [Related]

  • 9. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
    Yu DA, Kim YE, Kwon O, Park H.
    Indian J Dermatol Venereol Leprol; 2021 Aug 01; 87(5):621-627. PubMed ID: 34379968
    [Abstract] [Full Text] [Related]

  • 10. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY, Craiglow BG, Dai F, King BA.
    J Am Acad Dermatol; 2017 Jan 01; 76(1):22-28. PubMed ID: 27816293
    [Abstract] [Full Text] [Related]

  • 11. Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus.
    Udompanich S, Chanprapaph K, Suchonwanit P.
    Am J Clin Dermatol; 2018 Oct 01; 19(5):679-694. PubMed ID: 29948959
    [Abstract] [Full Text] [Related]

  • 12. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
    Brown L, Skopit S.
    J Drugs Dermatol; 2018 Aug 01; 17(8):914-917. PubMed ID: 30124734
    [Abstract] [Full Text] [Related]

  • 13. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
    Erduran F, Adışen E, Aksakal AB.
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun 01; 26(2):47-49. PubMed ID: 28632888
    [Abstract] [Full Text] [Related]

  • 14. [Alopecia areata with good response to tofacitinib].
    Maksimow A, Stintzing D, Wohlrab J.
    Hautarzt; 2021 Jun 01; 72(6):525-527. PubMed ID: 33044559
    [Abstract] [Full Text] [Related]

  • 15. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
    Guo L, Feng S, Sun B, Jiang X, Liu Y.
    J Eur Acad Dermatol Venereol; 2020 Jan 01; 34(1):192-201. PubMed ID: 31494993
    [Abstract] [Full Text] [Related]

  • 16. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, Borbon J, Clynes R, Christiano AM, Mackay-Wiggan J.
    J Invest Dermatol; 2018 Jul 01; 138(7):1539-1545. PubMed ID: 29452121
    [Abstract] [Full Text] [Related]

  • 17. Cross-sectional study of hair loss patterns in 122 Korean systemic lupus erythematosus patients: a frequent finding of non-scarring patch alopecia.
    Yun SJ, Lee JW, Yoon HJ, Lee SS, Kim SY, Lee JB, Lee SC, Won YH, Kim SJ.
    J Dermatol; 2007 Jul 01; 34(7):451-5. PubMed ID: 17584322
    [Abstract] [Full Text] [Related]

  • 18. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.
    Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, Abdalrahman Z, Sciumè G, Tsai WL, Trier AM, Nunez L, Mast L, Hoffmann V, Remaley AT, O'Shea JJ, Kaplan MJ, Gadina M.
    Arthritis Rheumatol; 2017 Jan 01; 69(1):148-160. PubMed ID: 27429362
    [Abstract] [Full Text] [Related]

  • 19. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY, Craiglow BG, King BA.
    J Am Acad Dermatol; 2018 Feb 01; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC, Marinkovich MP, Christiano AM, Oro AE, King BA.
    JCI Insight; 2016 Sep 22; 1(15):e89776. PubMed ID: 27699252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.